Camp4 Therapeutics Corporation Net Income per Employee (CAMP), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Camp4 Therapeutics Corporation  (NASDAQ: CAMP)
 

Camp4 Therapeutics Net Income per Employee

CAMP's Quarterly Results, Trends, Rankings, Statistics
Camp4 Therapeutics Corporation recorded a cumulative net loss of $-107 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 321 other companies achieving higher income per employee. While Camp4 Therapeutics's total ranking has deteriorated compared to the previous quarter from 3898 to 3963.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CAMP Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,234,250 -1,797,938 -1,675,063 -1,112,458 -1,078,813
CAMP's Total Ranking # 3963 # 3898 # 2692 # 2983 # 2854
Seq. Net Income Change - - - - -

CAMP Company Profile >> Back to CAMP Efficiency Comparisons >> Compare CAMP Net Income per Employee to its Competitors

CAMP Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 322
Healthcare Sector # 751
Overall Market # 3963

Net Income per Employee Statistics
High Average Low
$ 5,677,146 $ -42,039 $ -2,234,250
(Dec 31 2024)   (Jun 30 2026)




  News about Camp4 Therapeutics Corporation Income per employee

CAMP4 Therapeutics to Unveil Promising Preclinical Data at 28th ASGCT Annual Meeting Amid Challenging Market Condit...

CAMP4 Therapeutics is set to highlight new preclinical data from its innovative Urea Cycle Disorders and SYNGAP1-Related Disorders programs at the upcoming 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The presentation is expected to shed light on the potential of regRNA-targeting technology to significantly elevate protein levels by effectively upregulating gene expression, offering hope for patients suffering from these rare genetic conditions.The ASGCT Annual Meeting serves as a premier platform for showcasing cutting-edge advancements in gene and cell therapy, bringing together leading researchers and industry experts. CAMP4 s participation underscores its commitment to advancing therapeutic solutions that could address critical unmet medical needs, particularly in the realm of genetic disorders.

CalAmp Reinvents Itself: A Comprehensive Financial Restructuring to Drive Innovation and Growth


The Consumer Electronics industry has witnessed employees of 21 other companies achieving higher income per employee, highlighting the need for CalAmp to enhance its financial performance. Despite this, CalAmp s overall ranking has deteriorated compared to the first quarter of 2024, falling to 21.
CalAmp s decision to reduce debt and go private demonstrates its commitment to improving its financial position and focusing on long-term growth. By strengthening its financial flexibility, the company is better positioned to navigate the challenges in the market and drive innovation.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-02T20:50:02+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.